keyword
MENU ▼
Read by QxMD icon Read
search

CD30

keyword
https://www.readbyqxmd.com/read/28427693/a-case-of-cd30-alk1-anaplastic-large-cell-lymphoma-resembling-acute-disseminated-encephalomyelitis
#1
T Afrantou, K S Natsis, G Papadopoulos, R Lagoudaki, C Poulios, D Mamouli, I Kostopoulos, N Grigoriadis
Central nervous system involvement is an uncommon complication of systemic non-Hodgkin lymphomas. The majority of these cases concern B-cell lymphomas. We report a case of systemic T-cell anaplastic large cell lymphoma CD30+ ALK- with CNS involvement at the time of diagnosis and unusual MRI characteristics resembling acute disseminated encephalomyelitis.
April 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28427526/potential-application-and-prevalence-of-the-cd30-ki-1-antigen-among-solid-tumors-a-focus-review-of-the-literature
#2
REVIEW
Garrett K Berger, Kevin Gee, Cassandra Votruba, Ali McBride, Faiz Anwer
BACKGROUND: CD30 (Ki-1) is a cell membrane protein derived from the tumor necrosis factor (TNF) receptor family. The CD30 antigen has been associated primarily with Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Brentuximab vedotin (BV) is an antibody-drug conjugate targeting the CD30 antigen. FDA approval for BV includes relapsed and refractory HL and sALCL. The CD30 antigen also has been identified in many solid tumors, predominantly of germ cell origins and early clinical data is promising...
May 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28421369/immunophenotypic-profiles-for-distinguishing-orbital-mucosa-associated-lymphoid-tissue-lymphoma-from-benign-lymphoproliferative-tumors
#3
Shunichiro Ueda, Yoshihiko Usui, Takeshi Nagai, Daniel Diaz-Aguilar, Toshitaka Nagao, Hiroshi Goto
PURPOSE: To evaluate novel immunophenotypic profiles of patients with orbital lymphoproliferative tumors. METHODS: From 2006 to 2014, surgical biopsies from consecutive patients with newly diagnosed orbital mucosa-associated lymphoid tissue (MALT) lymphoma and IgG4-related ophthalmic disease (IgG4-ROD) were collected from Tokyo Medical University Hospital. A total of 44 tumors from 44 patients were analyzed, including 21 with orbital MALT lymphoma (11 men and 10 women, mean age 67...
April 18, 2017: Japanese Journal of Ophthalmology
https://www.readbyqxmd.com/read/28413663/breast-implant-associated-anaplastic-large-cell-lymphoma-and-the-role-of-brentuximab-vedotin-sgn-35-therapy-a-case-report-and-review-of-the-literature
#4
Kristin Richardson, Taha Alrifai, Kelly Grant-Szymanski, George J Kouris, Parameswaran Venugopal, Brett Mahon, Reem Karmali
Breast implant-associated (BIA) anaplastic large-cell lymphoma (ALCL) is a rare disease, comprising a small percentage of all non-Hodgkin lymphomas (NHLs), reportedly 2-3%. There is currently no established standard approach to the treatment of BIA ALCL. The first case on the development of ALCL in the presence of a breast implant was reported in 1997 and the association was first identified by the Food and Drug Administration in 2011. We herein describe a case of BIA ALCL in a patient with a previous history of breast cancer and breast reconstruction who presented with hardening of her breast implant...
April 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28402493/cd30-t-cells-in-late-seroma-may-not-be-diagnostic-of-breast-implant-associated-anaplastic-large-cell-lymphoma
#5
Marshall E Kadin, John Morgan, Haiying Xu, Caroline A Glicksman
HASH(0x2d17578)
April 11, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28402426/commentary-on-cd30-t-cells-in-late-seroma-may-not-be-diagnostic-of-breast-implant-associated-anaplastic-large-cell-lymphoma
#6
Mark W Clemens, Roberto N Miranda
No abstract text is available yet for this article.
April 11, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28402407/commentary-on-cd30-t-cells-in-late-seroma-may-not-be-diagnostic-of-breast-implant-associated-anaplastic-large-cell-lymphoma
#7
Anand K Deva
No abstract text is available yet for this article.
April 11, 2017: Aesthetic Surgery Journal
https://www.readbyqxmd.com/read/28400642/cd3-cd56-cd4-cd8-cd20-cd30-peripheral-t-cell-non-hodgkin-s-lymphoma-a-rare-case-report
#8
Ashish Jagati, Bela J Shah, Sonal Tibrewal, Trusha Gajjar
Cutaneous T-cell lymphoma (CTCL) commonly presents as mycosis fungoides or Sezary syndrome, both having CD4 positivity. A subset of CTCL which lacks CD4 surface marker is classified as cutaneous γ and δ-T-cell lymphoma (CGD-TCL). Because of its rarity and inability to study large number of patients, the impact of immunophenotype on the clinical outcome of primary CTCL in patients is limited. We report a case of primary CGD-TCL in a 71-year-old male because of this rarity and to emphasize its aggressive nature...
March 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28400635/oral-and-cutaneous-lymphomas-other-than-mycosis-fungoides-and-s%C3%A3-zary-syndrome-in-a-mexican-cohort-recategorization-and-evaluation-of-international-geographical-disparities
#9
Amparo Hernández-Salazar, Jorge Andrés García-Vera, Yann Charli-Joseph, Guadalupe Ortiz-Pedroza, Silvia Méndez-Flores, Rocío Orozco-Topete, Ana Lilia Morales-Leyte, Judith Domínguez-Cherit, Carmen Lome-Maldonado
BACKGROUND: Nonmycosis fungoides/Sézary syndrome (non-MF/SS) primary cutaneous lymphomas (PCL) are currently categorized under the 2005-World Health Organization/European Organization for Research and Treatment of Cancer (WHO-EORTC) classification for PCL. These differ in behavior from secondary cutaneous lymphomas (SCL) and to lymphomas limited to the oral cavity (primary oral lymphomas [POL]) both categorized under the 2016-WHO classification for lymphoid neoplasms. AIMS: This study aims to report the first series of non-MF/SS PCL, SCL, and POL in a Mexican cohort, examine the applicability of current classification systems and compare our findings with those from foreign cohorts...
March 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28400633/new-targeted-treatments-for-cutaneous-t-cell-lymphomas
#10
Martine Bagot
Cutaneous T-cell lymphomas (CTCLs) represent a group of rare and heterogeneous diseases that are very difficult to treat at advanced stages. The development of monoclonal antibodies is a new hope for the treatment of these diseases. Alemtuzumab (Campath) is a humanized IgG1 kappa monoclonal antibody specific for CD52, an antigen expressed by most T and B lymphocytes. Alemtuzumab may frequently induce long-term remissions in patients with Sezary syndrome but high-dose treatments lead to severe cytopenia, immune depletion, and opportunistic infections...
March 2017: Indian Journal of Dermatology
https://www.readbyqxmd.com/read/28398275/natural-killer-t-cell-lymphomas-in-pediatric-and-adolescent-patients
#11
REVIEW
Amanda M Termuhlen
Natural killer/T-cell (NK/T-cell) lymphomas are rare in children and adolescents and consist predominantly of nasal-type extranodal NK/T-cell lymphomas. More than half of pediatric/adolescent patients with NK/T-cell lymphomas present with localized nasal/sinus involvement, but the disease may involve many organs. NK/T-cell lymphoma cells are cytotoxic and associated with necrosis and angioinvasion; they express CD56, CD2, cytoplasmic CD3 epsilon, and to a variable degree CD30. The cells contain Epstein-Barr virus (EBV)-encoded RNA...
March 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28381153/alk-negative-anaplastic-large-cell-lymphoma-presenting-as-an-extranodal-soft-tissue-mass-with-an-unusual-alveolar-growth-pattern
#12
Badr AbdullGaffar, Rania M Seliem
Anaplastic large cell lymphoma (ALCL) is a T-cell lymphoma which has been recognized to have a variable clinical presentation and a broad spectrum of histomorphologic features. Its variable histomorphologic appearances are sometimes diagnostically challenging for the pathologists since they can mimic sarcomas, melanomas and undifferentiated carcinomas. To our knowledge, a previous case of axillary soft-tissue mass of ALK-positive ALCL with an alveolar growth pattern has been so far reported in the literature...
March 1, 2017: International Journal of Surgical Pathology
https://www.readbyqxmd.com/read/28377796/redox-regulating-enzymes-and-connected-microrna-regulators-have-prognostic-value-in-classical-hodgkin-lymphomas
#13
Peeter Karihtala, Katja Porvari, Ylermi Soini, Kirsi-Maria Haapasaari
There are no previous studies assessing the microRNAs that regulate antioxidant enzymes in Hodgkin lymphomas (HLs). We determined the mRNA levels of redox regulating enzymes peroxiredoxins (PRDXs) I-III, manganese superoxide dismutase (MnSOD), nuclear factor erythroid-derived 2-like 2 (Nrf2), and Kelch-like ECH-associated protein 1 (Keap1) from a carefully collected set of 41 classical HL patients before receiving any treatments. The levels of redoxmiRs, miRNAs known to regulate the above-mentioned enzymes, were also assessed, along with CD3, CD20, and CD30 protein expression...
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/28359170/immunotherapy-for-the-treatment-of-hodgkin-lymphoma
#14
Eva M Donato, Miguel Fernández-Zarzoso, Javier De La Rubia
Most patients with Hodgkin lymphoma (HL) enjoy durable remissions following front-line treatment but 30% of patients are refractory or relapse after first line therapy. Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) can cure an additional 50-55% of relapsing patients but new treatments are needed for patients with HL who are refractory or relapse after ASCT. Immunotherapy has emerged as a promising treatment for the management of these patients. The availability of the anti-CD30 antibody brentuximab vedotin and new targeted drugs such as immune checkpoint inhibitors, show promising clinical activity in patients with HL and are important milestones for the management of patients with HL particularly for those who have progressed after standard initial therapy and ASCT...
April 12, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28351978/mouse-model-of-epstein-barr-virus-lmp1-and-lmp2a-driven-germinal-center-b-cell-lymphoproliferative-disease
#15
Takeharu Minamitani, Yijie Ma, Hufeng Zhou, Hiroshi Kida, Chao-Yuan Tsai, Masanori Obana, Daisuke Okuzaki, Yasushi Fujio, Atsushi Kumanogoh, Bo Zhao, Hitoshi Kikutani, Elliott Kieff, Benjamin E Gewurz, Teruhito Yasui
Epstein-Barr virus (EBV) is a major cause of immunosuppression-related B-cell lymphomas and Hodgkin lymphoma (HL). In these malignancies, EBV latent membrane protein 1 (LMP1) and LMP2A provide infected B cells with surrogate CD40 and B-cell receptor growth and survival signals. To gain insights into their synergistic in vivo roles in germinal center (GC) B cells, from which most EBV-driven lymphomas arise, we generated a mouse model with conditional GC B-cell LMP1 and LMP2A coexpression. LMP1 and LMP2A had limited effects in immunocompetent mice...
March 28, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28348271/identification-of-novel-stat6-regulated-proteins-in-mouse-b-cells-by-comparative-transcriptome-and-proteome-analysis
#16
Lavanya Mokada-Gopal, Alexander Boeser, Christian H K Lehmann, Friedel Drepper, Diana Dudziak, Bettina Warscheid, David Voehringer
The transcription factor STAT6 plays a key role in mediating signaling downstream of the receptors for IL-4 and IL-13. In B cells, STAT6 is required for class switch recombination to IgE and for germinal center formation during type 2 immune responses directed against allergens or helminths. In this study, we compared the transcriptomes and proteomes of primary mouse B cells from wild-type and STAT6-deficient mice cultured for 4 d in the presence or absence of IL-4. Microarray analysis revealed that 214 mRNAs were upregulated and 149 were downregulated >3-fold by IL-4 in a STAT6-dependent manner...
March 27, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28342276/primary-cutaneous-anaplastic-large-cell-lymphoma
#17
REVIEW
Ryanne A Brown, Sebastian Fernandez-Pol, Jinah Kim
Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a CD30+ lymphoproliferative disorder (LPD) of the skin with a relatively good prognosis in the absence of high-stage disease.[1] CD30+ LPDs comprise approximately 25-30% of primary cutaneous lymphomas and as a group represent the second most common clonal T cell neoplasm of the skin behind mycosis fungoides (MF).
March 25, 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28341790/tumor-associated-macrophages-can-contribute-to-antitumor-activity-through-fc%C3%AE-r-mediated-processing-of-antibody-drug-conjugates
#18
Fu Li, Michelle Ulrich, Mechthild Jonas, Ivan J Stone, Germein Linares, Xinqun Zhang, Lori Westendorf, Dennis R Benjamin, Che-Leung Law
The primary mechanism of antibody-drug conjugates (ADCs) is targeted delivery of a cytotoxic payload to tumor cells via cancer-associated membrane receptors. However, the tumor microenvironment likely plays a role in ADC penetration, distribution, and processing and thus impacts the overall antitumor activity. Here, we report on the potential contribution of Fc-FcγR interactions between ADCs and tumor-associated macrophages (TAMs) to the preclinical antitumor activities of ADCs. In the CD30+ L-428 Hodgkin lymphoma model, anti-CD30-vcMMAE and a non-binding control (hIgG-vcMMAE) demonstrated similar antitumor activity as well as similar payload release in the tumors...
March 24, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28341757/elevated-serum-levels-of-scd30-and-il-6-and-detectable-il-10-precede-classical-hodgkin-lymphoma-diagnosis
#19
Lynn I Levin, Elizabeth C Breen, Brenda M Birmann, Julie L Batista, Larry I Magpantay, Yuanzhang Li, Richard F Ambinder, Nancy E Mueller, Otoniel Martínez-Maza
BACKGROUND: We investigated whether an immune system environment characterized by elevated serum levels of B-cell activation molecules was associated with the subsequent development of classical Hodgkin lymphoma (cHL). METHODS: We measured serum levels of B cell stimulatory cytokines, interleukin (IL)-6 and IL-10, soluble CD30 (sCD30) and total IgE prior to cHL diagnosis in 103 cases and 206 matched controls with archived specimens in the DoD Department of Defense Serum Repository...
March 24, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28340881/cd30-lymphoproliferative-disorders-of-the-skin
#20
REVIEW
Maxwell B Sauder, John T O'Malley, Nicole R LeBoeuf
Primary cutaneous CD30(+) lymphoproliferative disorders encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and indeterminate cases. LyP is a benign disorder characterized by recurrent crops of red or violaceous papulonodules. Patients with LyP are at an increased risk of a secondary malignancy. pcALCL is characterized by a solitary red to violaceous nodule or tumor larger than 20 mm. LyP is benign, is limited to the skin, and self-resolves, with a 5-year survival rate of 100%; pcALCL is limited to the skin and responsive to directed therapies, with a 5-year survival rate of over 95%...
April 2017: Hematology/oncology Clinics of North America
keyword
keyword
73698
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"